Editor’s note: This is a developing news story. Please check back soon for updates.
Harrow has completed its deal to acquire Melt Pharmaceuticals, according to a company press release.
Harrow announced its plan to acquire Melt in September and said it planned to submit a new drug application for MELT-300, a sublingually delivered sedation product.
MELT-300 — a formulation of a fixed dose of midazolam (3 mg) and ketamine (50 mg) — previously demonstrated superiority to midazolam alone. The company said the therapy has the potential to change patient experiences in a variety of outpatient- and